Key Developments: Cepheid (CPHD.O)
38.23USD
23 May 2013
$-0.03 (-0.08%)
$38.26
$37.95
$38.36
$37.14
346,400
397,614
$46.00
$28.12
Latest Key Developments (Source: Significant Developments)
Cepheid Reaffirms FY 2013 Guidance
Cepheid announced that for fiscal 2013, it continues to expects total revenue to be in the range of $375 to $385 million; Net income to range from a net loss of $(0.05) to net income of $0.01 per share and Non-GAAP net income in the range of $0.41 to $0.46 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $381 million and EPS of $0.44 for fiscal 2013. Full Article
Cepheid Announces Board Of Directors Changes
Cepheid announced that its Board of Directors has elected John Bishop as Chairman of the Board of Directors and named Cristina Kepner as Lead Independent Director, effective February 12, 2013. Mr. Bishop, currently Cepheid's Chief Executive Officer, succeeds Thomas Gutshall, who will continue to serve on Cepheid's board as a director. Mr. Bishop has been Cepheid's Chief Executive Officer and a director since April 2002. Full Article
Cepheid Issues FY 2013 Guidance
Cepheid announced that for fiscal 2013, it expects revenue to be in the range of $375 to $385 million, Net income to be in the range from a net loss of $(0.05) to net income of $0.01 per share, Non-GAAP net income in the range of $0.41 to $0.46 per share. Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles. Full Article
Cepheid Receives FDA Clearance For Xpert CT/NG, Delivering Rapid Detection And Differentiation Of Chlamydia And N. Gonorrhoeae
Cepheid announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert CT/NG. Running on Cepheid's GeneXpert Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States. Full Article
Cepheid Reaffirms FY 2012 Revenue Guidance-Conference Call
Cepheid announced that for fiscal 2012, it expects total revenue to be approximately $333 million. Full Article
Cepheid Reaffirms FY 2012 Guidance; Lowers FY 2012 EPS Guidance
Cepheid announced that for fiscal 2012, it expects total revenue to be approximately $333 million, Net loss per share in the range of $(0.42)-$(0.40) and non-GAAP net income per share in the range of $0.21-$0.23. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $333 million and EPS of $(0.07) for fiscal 2012. Full Article
Cepheid Issues Q3 2012 Revenue Guidance Below Analysts' Estimates; Reaffirms FY 2012 Revenue Guidance
Cepheid announced that for the third quarter of 2012, it expects revenue to be in the range of $79 to $81 million. For fiscal 2012, it continues to expect total revenue to be in the range of $333 to $347 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $84 million for the third quarter of 2012 and revenues of $334 million for fiscal 2012. Full Article
Cepheid, Inc. Reaffirms FY 2012 Revenue Guidance; Lowers FY 2012 EPS Guidance
Cepheid, Inc. announced that for fiscal 2012, it expects revenue to be in the range of $333-$347 million. Net income per share in the range of $0.00-$0.04 and Non-GAAP net income per share in the range of $0.38 to $0.42. Expected non-GAAP net income per share excludes the effect of approximately $26 million related to stock-based compensation expense, approximately $2.8 million related to the amortization of acquired intangibles, and a $1.8 million tax benefit related to an intercompany intellectual property transaction. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $341 million for fiscal 2012. Full Article
Cepheid, Inc. Reaffirms FY 2012 Revenue Guidance; Lowers FY 2012 EPS Guidance
Cepheid, Inc. announced that for fiscal 2012, it expects revenue to be in the range of $333-$347 million, net income to be in the range of $0.12-$0.17 per share and non-GAAP net income (EPS) to be in the range of $0.50-$0.55 per share. Expected non-GAAP net income excludes approximately $26 million related to stock-based compensation expense, approximately $2.8 million related to the amortization of acquired intangibles, and a $1.8 million tax benefit related to an intercompany intellectual property transaction. The fully diluted share count for the year is expected to be between 70-71 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $342 million and EPS of $0.60 for fiscal 2012. Full Article
Cepheid, Inc. Issues FY 2012 Guidance; Revenue Guidance In Line With Analysts' Estimates
Cepheid, Inc. announced that for fiscal 2012, it expects total revenue to be in the range of $333-$347 million; net income in the range of $0.17 to $0.24 per share; Non-GAAP net income in the range of $0.55 to $0.60 per share. Expected non-GAAP net income excludes approximately $26 million related to stock compensation expense, approximately $2 million related to the amortization of acquired intangibles, and up to a $1.9 million non-cash tax benefit relating to a potential change to international tax and legal entity structure. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $333 million for fiscal 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
